Diagnosis and classification of Kawasaki disease

Journal of Autoimmunity

Volumn 48-49, Issue , 2014, Pages 113-117

  Sánchez Manubens, Judith ^a   Bou, Rosa ^a   Anton, Jordi ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Child; Coronary aneurysm; Fever; Intravenous immunoglobulins; Mucocutaneous lymph node syndrome

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; ETANERCEPT; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; IMMUNOGLOBULIN; INFLIXIMAB; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ARTICLE; CHAPPED LIPS; CLINICAL FEATURE; DESQUAMATION; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CLASSIFICATION; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; FEVER; FOOT EDEMA; HAND EDEMA; HUMAN; HYPEREMIA; LABORATORY DIAGNOSIS; LEUKOCYTOSIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; NORMOCHROMIC NORMOCYTIC ANEMIA; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PYURIA; RASH; SENSITIVITY AND SPECIFICITY; THROMBOCYTOSIS;

CHILD; CORONARY ANEURYSM; FEVER; INTRAVENOUS IMMUNOGLOBULINS; MUCOCUTANEOUS LYMPH NODE SYNDROME;

ACUTE DISEASE; ASIA; AUTOANTIBODIES; CALIFORNIA; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HAWAII; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULINS, INTRAVENOUS; INCIDENCE; MUCOCUTANEOUS LYMPH NODE SYNDROME;

EID: 84895863405     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2014.01.010     Document Type: Article

References (51)

1. Ozen S., Ruperto N., Dillon M.J., Bagga A., Barron K., Davin J.C., et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 2006, 65(7):936-941.
2. Kawasaki K., China K., Nishijima M. Release of lipopolysaccharide deacylase PagL from latency compensates for a lack of lipopolysaccharide aminoarabinose modification-dependent resistance to antimicrobial peptide polymyxin B in Salmonella enterica. JBacteriol 2007, 189(13):4911-4919.
3. Nakamura Y., Yashiro M., Uehara R., Sadakane A., Tsuboi S., Aoyama Y., et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2009-2010 nationwide survey. JEpidemiol 2012, 22(3):216-221.
4. Holman R.C., Belay E.D., Christensen K.Y., Folkema A.M., Steiner C.A., Schonberger L.B. Hospitalizations for Kawasaki syndrome among children in the United States, 1997-2007. Pediatr Infect Dis J 2010, 29:483-488.
5. Fischer T.K., Holman R.C., Yorita K.L., Belay E.D., Melbye M., Koch A. Kawasaki syndrome in Denmark. Pediatr Infect Dis J 2007, 26:411-415.
6. Heuclin T., Dubos F., Hue V., Godart F., Francart C., Vincent P. Increased detection rate of Kawasaki disease using new diagnostic algorithm, including early use of echocardiography. JPediatr 2009, 155:695-699.
7. Yim D., Curtis N., Cheung M., Burgner D. An update on Kawasaki disease II: clinical features, diagnosis, treatment and outcomes. JPaediatr Child Health 2013, 49(8):614-623.
8. Yim D., Curtis N., Cheung M., Burgner D. Update on Kawasaki disease: Epidemiology, aetiology and pathogenesis. JPaediatr Child Health 2013, 49(8):614-623.
9. Manlhiot Cedric, Yeung Rae S.M., Clarizia Nadia A., Chahal Nita, Brian W. Kawasaki disease at the extremes of the age spectrum. Pediatrics 2009, 124:e410.
10. Nakagawa N., Yoshida M., Narahara K., Kunitomi T. Kawasaki disease in an 8-day-old neonate. Pediatr Cardiol 2009, 30:527-529.
11. Stanley T.V., Grimwood K. Classical Kawasaki disease in a neonate. Arch Dis Child Fetal Neonatal Ed 2002, 86:F135-F136.
12. Inokuchi R., Kurata H., Harada M., Aoki Y., Matsubara T., Doi K., et al. Coronary artery aneurysms after adult-onset Kawasaki disease. Circulation 2013, 127(15):1636-1637.
13. Stankovic K., Miailhes P., Bessis D., Ferry T., Broussolle C., Seve P. Kawasaki-like syndromes in HIV-infected adults. JInfect 2007, 55:488-494.
14. Burns J.C., Cayan D.R., Tong G., Bainto E.V., Turner C.L., Shike H., et al. Seasonality and temporal clustering of Kawasaki syndrome. Epidemiology 2005, 16(2):220-225.
15. Dergun M., Kao A., Hauger S.B., Newburger J.W., Burns J.C. Familial occurrence of Kawasaki syndrome in North America. Arch Pediatr Adolesc Med 2005, 159(9):876-881.
16. Hirata S., Nakamura Y., Yanagawa H. Incidence rate of recurrent Kawasaki disease and related risk factors: from the results of nationwide surveys of Kawasaki disease in Japan. Acta Paediatr 2001, 90:40-44.
17. Fujita Y., Nakamura Y., Sakata K., Hara N., Kobayashi M., Nagai M., et al. Kawasaki disease in families. Pediatrics 1989, 84:666-669.
18. Shimizu C., Kim J., Stepanowsky P., Trinh C., Lau H.D., Akers J.C., et al. Differential expression of miR-145 in children with Kawasaki disease. PLoS ONE 2013, 8(3):e58159.
19. Rowley A.H., Baker S.C., Orenstein J.M., Shulman S.T. Searching for the cause of Kawasaki disease-cytoplasmic inclusion bodies provide new insight. Nat Rev Microbiol 2008, 6:394-401.
20. Rowley A.H. Kawasaki disease: novel insights into etiology and genetic susceptibility. Annu Rev Med 2011, 62:69-77.
21. Rodó X., Ballester J., Cayan D., Melish M.E., Nakamura Y., Uehara R., et al. Association of Kawasaki disease with tropospheric wind patterns. Sci Rep 2011, 1:152.
22. Onouchi Y., Ozaki K., Buns J.C., Shimizu C., Hamada H., Honda T., et al. Common variants in CASP3 confer susceptibility to Kawasaki disease. Hum Mol Genet 2010, 19:2898-2906.
23. Burgner D., Davila S., Breunis W.B., et al. Agenome-wide association study identifies novel and functionally related susceptibility loci for Kawasaki disease. PLoS Genet 2009, 5:e1000319.
24. Kim J.J., Hong Y.M., Sohn S., et al. Agenome-wide association analysis reveals 1p31 and 2p13.3 as susceptibility loci for Kawasaki disease. Hum Genet 2011, 129:487-495.
25. Tsai F.J., Lee Y.C., Chang J.S., et al. Identification of novel susceptibility loci for Kawasaki disease in a Han Chinese population by a genome-wide association study. PloS ONE 2011, 6:e16853.
26. Khor C.C., Davila S., Breunis W.B., Lee Y.C., Shimizu C., Wright V.J., et al. Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. Nat Genet 2011, 43:1241-1246.
27. Newburger J.W., Takahashi M., Gerber M.A., Gewitz M.H., Tani L.Y., Burns J.C., et al. Diagnosis, treatment, and long-term differential diagnosis of KD. Management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, American heart association. Pediatrics 2004, 114(6):1708-1733.
28. Smith L.B., Newburger J.W., Burns J.C. Kawasaki syndrome and the eye. Pediatr Infect Dis J 1989, 8(2):116-118.
29. Suddleson E.A., Reid B., Woolley M.M., Takahashi M. Hydrops of the gallbladder associated with Kawasaki syndrome. JPediatr Surg 1987, 22(10):956-959.
30. Novo A., Pinto S., Prior A.C., Alvares S., Soares T., Guedes M. Kawasaki disease and sensorineural hearing loss: an (un)expected complication. Eur J Pediatr 2012, 171(5):851-854.
31. Magalhães C.M., Magalhães Alves N.R., Oliveira K.M., Silva I.M., Gandolfi L., Pratesi R. Sensorineural hearing loss: an underdiagnosed complication of Kawasaki disease. JClin Rheumatol 2010, 16(7):322-325.
32. Amano S., Hazama F. Neural involvement in Kawasaki disease. Acta Pathol Jpn 1980, 30(3):365-373.
33. Garcia P.S., Staines B.T., Hernandez B.,V., Yamazaki Nakashimada M.A. Reactivation of the scar of BCG vaccination in Kawasaki's disease: clinical case and literature review. Rev Alerg Mex 2006, 53(2):76-78.
34. Chiang A.N., Hwang B., Shaw G.C., Lee B.C., Lu J.H., Meng C.C., et al. Changes in plasma levels of lipids and lipoprotein composition in patients with Kawasaki disease. Clin Chim Acta 1997, 260(1):15-26.
35. Harada K. Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr Jpn 1991, 33:805-810.
36. Giannouli G., Tzoumaka-Bakoula C., Kopsidas I., Papadogeorgou P., Chrousos G.P., Michos A. Epidemiology and risk factors for coronary artery abnormalities in children with complete and incomplete Kawasaki disease during a 10-year period. Pediatr Cardiol 2013, 34(6):1476-1481.
37. Kobayashi T., Inoue Y., Takeuchi K., Okada Y., Tamura K., Tomomasa T., et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006, 113(22):2606-2612.
38. Seki M., Kobayashi T., Kobayashi T., Morikawa A., Otani T., Takeuchi K., et al. External validation of a risk score to predict intravenous immunoglobulin resistance in patients with Kawasaki disease. Pediatr Infect Dis J 2011, 30(2):145-147.
39. Egami K., Muta H., Ishii M., Suda K., Sugahara Y., Iemura M., et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. JPediatr 2006, 149(2):237-240.
40. Tremoulet A.H., Best B.M., Song S., Wang S., Corinaldesi E., Eichenfield J.R., et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. JPediatr 2008, 153(1):117-121.
41. Saundel R., Petty R. Kawasaki disease. Textbook of pediatric rheumatology 2005, 521-538. Elsevier Saunders. J. Cassidy, R. Petty, R. Laxer, C. Lindsley (Eds.).
42. Durongpisitkul K., Gururaj V.J., Park J.M., Martin C.F. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995, 96(6):1057-1061.
43. Nagashima M., Matsushima M., Matsuoka H., Ogawa A., Okumura N. High-dose gammaglobulin therapy for Kawasaki disease. JPediatr 1987, 110(5):710-712.
44. Lee G., Lee S.E., Hong Y.M., Sohn S. Is high-dose aspirin necessary in the acute phase of kawasaki disease?. Korean Circ J 2013, 43:182-186.
45. Wallace C.A., French J.W., Kahn S.J., Sherry D.D. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 2000, 105(6):E78.
46. Kobayashi T., Kobayashi T., Morikawa A., Ikeda K., Seki M., Shimoyama S., et al. Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease. JPediatr 2013, 163(2):521-526.
47. Weiss J.E., Eberhard B.A., Chowdhury D., Gottlieb B.S. Infliximab as a novel therapy for refractory Kawasaki disease. JRheumatol 2004, 31:808-810.
48. Tremoulet A.H., Pancoast P., Franco A., Bujold M., Shimizu C., Onouchi Y., et al. Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease. JPediatr 2012, 161(3):506-512.
49. Cohen S., Tacke C.E., Straver B., Meijer N., Kuipers I.M., Kuijpers T.W. Achild with severe relapsing Kawasaki disease rescued by IL-1 receptor blockade and extracorporeal membrane oxygenation. Ann Rheum Dis 2012, 71(12):2059-2061.
50. Ohashi R., Fukazawa R., Watanabe M., Tajima H., Nagi-Miura N., Ohno N., et al. Etanercept suppresses arteritis in a murine model of Kawasaki disease: a comparative study involving different biological agents. Int J Vasc Med 2013, 2013:543141.
51. Alexoudi I., Kanakis M., Kapsimali V., Vaiopoulos G. Kawasaki disease: current aspects on aetiopathogenesis and therapeutic management. Autoimmun Rev 2011, 10(9):544-547.